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Abstract
Enteric fever is a bacterial infection caused by Salmonella typhi and paratyphi. 
It is endemic in many parts of Africa and South Asia where there is poor access to 
safe portable water and below par food quality assurance. It is important to ensure 
prompt recognition, diagnosis and management of symptoms to forestall complica-
tions. Due to the rising global burden, significant effort has to be made to improve 
primary care services like vaccination, antimicrobial stewardship and encourage-
ment of hygiene measures. Hence, it is imperative to be aware of its current burden 
and options available in primary care for its prevention and treatment.
Keywords: Salmonella, enteric fever, typhoid, primary care, typhoid-conjugate 
vaccine
1. Introduction
Typhoid fever (now more appropriately called Enteric fever) is a bacterial 
infectious disease caused by Salmonella enterica subspecies enterica and serovar 
typhi. It is mainly transmitted through the faeco-oral route via contaminated food, 
water and asymptomatic carriers [1]. It is endemic in developing countries and low-
resource settings where hygiene and sanitation measures are subpar. In developed 
countries and high-income settings, it is less common but cases still occur in recent 
travellers to endemic areas [2]. There are a number of factors which contribute to 
the disease burden including lack of access to clean, portable water, poor food qual-
ity control and lack of public health services (e.g well managed public latrine and 
hand washing facilities); all of which can be attributed to lack of awareness, low 
political will and sociocultural factors. Symptoms of enteric fever vary significantly 
and are generally nonspecific. These include pyrexia, headache, myalgia, arthralgia, 
nausea, rash, abdominal pain, constipation and occasionally diarrhoea [3].
Enteric fever, if left untreated can be life-threatening and result in a myriad of 
complications including intestinal haemorrhage and perforation, peritonitis, sepsis, 
meningitis, osteomyelitis, multiorgan failure and death [1, 3]. Hence, it is expedient 
to ensure early diagnosis and management to mitigate complications.
Central to the actualisation of universal health coverage is an effective primary 
health care system which is usually the first point of contact for most patients. 
Hence, the role of the primary care clinician in the prevention, diagnosis and 
management of enteric fever and its complications cannot be overemphasised. This 
is what this chapter aims to address.
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2. Epidemiology
Enteric fever is a global health problem affecting 21.6 million people (incidence 
of 3.6 per 1000 population) and resulting in just over 216 000 deaths annually 
[4]. It is endemic in developing and low and middle income countries of Africa, 
Asia, Latin America, the Caribbean and Oceania mainly due to poor sanitation 
and environmental hygiene [2, 4]. Bangladesh, Indonesia, China, India, Laos, 
Nepal, Pakistan and Vietnam account for 80% of cases [4]. Untreated, 10%–30% 
of patients will die but mortality reduces to 1%–4% with prompt and appropriate 
treatment. In the pre-antibiotics era, the USA had a case fatality rate of 9%–13% 
[5]. This illustrates how much the discovery of antibiotics has revolutionised its 
management, just like most bacterial infections. However, there is an increasing 
burden of antimicrobial resistant Salmonella strains emanating from endemic 
countries mainly due to poor antimicrobial stewardship and measures must be 
taken to stem the tide.
Significant intra- and intercountry variation in disease burden exists in many 
regions of south and south east Asia and parts of Africa. For instance, surveillance 
performed in two sites in Kenya between 2006 and 2009 found that the incidence 
of blood-culture proven typhoid fever in rural and urban sites varied from 29 
up to 247-cases/100 000 person-years [6]. Also, data from the Diseases of Most 
Impoverished areas have described incidence rates varying from 24.2/100 000 in 
Vietnam to 493.5/100 000 in parts of India [7]. However, most disease burden data 
from low- and middle-income countries are hospital-based which leaves a huge 
number of cases unaccounted especially in areas of low health-care usage and 
accessibility. Hence, it is imperative for countries in endemic regions of the world 
to develop a national and regional surveillance system to identify factors respon-
sible for these variations and adopt guidelines and protocols to improve efficiency 
in prevention, diagnosis and management. Central to this should be an efficient 
primary care system where surveillance and data gathering can be co-ordinated and 
synchronised with hospital-based data providing a broad-based approach and a 
better reflection of disease burden.
The incidence of enteric fever varies by age. In endemic areas, incidence is 
higher in younger children but similar across age groups in low burden areas [8]. In 
general, children are at a higher risk of complications including ileitis and intestinal 
perforation. When perforation sets in, mortality has been reported to be as high as 
62% [9, 10]. Therefore, it is imperative that signs and symptoms of enteric fever are 
identified and treated early in primary care. Due to the wide disparity in incidence 
between developed and low and middle-income countries, primary care physicians 
in the latter will most likely see a lot more cases and have a high pre-test probability. 
This poses a challenge for a lot of primary care practitioners in developed countries 
who are less likely to be familiar with its presentation and may result in delay in 
diagnosis. In England and Wales, any case of Salmonella infection is a notifiable 
disease which must be reported to Public Health England and may require urgent 
community investigation to forestall an outbreak [11].
3. Aeotiopathogenesis
Salmonella is a flagellated, non-capsulated facultative anaerobic gram-negative 
bacilli and non-lactose fermenter of the Enterobacteriaceae family which has 
flagellar, somatic and outer coat antigens [7, 12]. Its outermost covering is made up 
of the somatic O antigen while the flagellae are composed of the H antigen. Each 
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O and H antigen have a unique code number and a varied combination of these 
form the basis for the determination of serotypes [12]. Of the over 2500 serotypes 
of Salmonella that have been identified, only 100 are thought to be responsible for 
most human infections [7]. These infections can be broadly divided into nonty-
phoidal and typhoidal. The typhoidal infection is mainly caused by S. typhi and less 
commonly paratyphi. Salmonella typhi and paratyphi A are thought to be restricted 
to humans alone. A key virulence factor in most strains of S.typhi is the Vi capsular 
antigen which possesses immunomodulatory properties that are thought to contrib-
ute to disease pathogenesis, including limiting complement deposition, reducing 
immune activation, assisting with phagocytosis evasion, and inhibiting serum 
bactericidal activity [7, 13, 14]. Without it, S. typhi will be more susceptible to 
attack and destruction by the host immune system. Hence, the Vi antigen has been 
harnessed as a major component of typhoid vaccines including the new conjugate 
vaccines [7].
Transmission is through the faeco-oral route from contaminated food, water and 
unrestricted contact with chronic carriers especially in an unhygienic environment. 
When Salmonella typhi is ingested, it evades degradation by enzymes and gastric 
acid before entering the host’s system primarily through the terminal ileum [15]. At 
the distal ileum, through specialised structures called fimbrae, they attach to the 
epithelial cells overlying clusters of lymphoid tissues called Peyer patches. These 
serve as a relay point for macrophages travelling from the gut to the lymphatic sys-
tem. Activation of the macrophages at the Peyer’s patches release cytokines which 
attract more macrophages to the site. These macrophages serve as a vehicle by which 
S. typhi is transported to several parts of the reticuloendothelial system including 
the liver, spleen and bone marrow where they replicate up to a critical density at this 
point [16], they break into the bloodstream and invade other parts of the body. One 
of such places invaded is the gall bladder. The gall bladder is infected haematog-
enously or through infected bile. Infected bile is then secreted into the gut where it 
once again comes in contact with the Peyer patches at the distal ileum. This second 
sensitization of the macrophages at this site results in inflammation and hypertro-
phy of the lymphoid tissues (typhoid ileitis) [15, 16]. This enlargement encroaches 
on the blood supply resulting in ischaemic coagulative necrosis and consequently 
perforation and peritonitis. Some of the salmonella is excreted in the stool which 
is serves as a source of infection spread. This is the source of transmission of 
Salmonella in chronic carriers where the salmonella is thought to avoid enzymatic 
and chemical degradation in the gall bladder for a long time by forming biofilms or 
entering an intracellular ‘comfort zone’ in the gall bladder epithelium.
4. Clinical presentation
Enteric fever presents with a number of nonspecific symptoms and a wide varia-
tion in severity. Symptoms must be correlated with laboratory investigation to reach 
a diagnosis. Symptoms generally include fever, constipation, diarrhoea, abdominal 
pain, lethargy, nausea and vomiting, malaise, headache, truncal rash (rose spot), 
anorexia etc. The incubation period for enteric fever is 1–3 weeks and symptoms 
progressively get worse over the course of illness if not promptly treated [17].
In the first week, patients may complain of headache, malaise, intermittent 
fever, cough and constipation. Bradycardia may also be elicited on clinical examina-
tion. In the presence of fever, this is termed Faget sign or sphygmothermic dis-
sociation. This is also seen in yellow fever, Brucellosis, Tularaemia and Colorado 
Tick fever.
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In the second week, the patient appears dull with diarrhoea and apathy, sus-
tained pyrexia, distended, tender abdomen and sometimes red macules (rose 
spots). Splenomegaly may also be present in 75% of cases.
In the third week if still untreated, patient become very ill, delirious and toxic with 
high pyrexia, intestinal haemorrhage and perforation. Toxic myocarditis may also ensue.
10% of cases relapse within the first 3 weeks of apparent recovery or completion 
of treatment, hence adequate monitoring and follow up should be arranged.
In the United Kingdom, any Salmonella infection is notifiable to Public Health 
England. Most cases occur in travellers returning from endemic areas. The PHE has 
developed certain criteria which would serve as an invaluable tool especially for 
primary care physicians in the early identification of suspicious cases for further 
escalation, assessment and confirmation.
According to Public Health England (PHE), cases can be classified into con-
firmed, possible and probable cases based on the following criteria [18]:
It must be noted that the typical presentation of course of enteric fever may 
deviate significantly from that described above. These may include pneumonia, 
delirium, arthralgias and severe jaundice. Younger children, people living with 
AIDS and one third of immunocompetent adults may present with diarrhoea 
instead of the classical constipation. The typical step ladder pyrexia is now only 
seen I 12% of cases with the fever pattern now mostly of the insidious persistent 
type [7]. Untreated or poorly treated infections may result in orchitis, intestinal 
ileitis, haemorrhage and perforation, meningitis, osteomyelitis.
5. Diagnosis
The diagnosis of enteric fever is made by correlation of clinical and laboratory 
investigations. The current gold standard as recommended by the world health 
Confirmed Case Probable Case Possible Case
• A person with S. typhi or S. 
paratyphi infection deter-




• A person with documented 
confirmatory evidence from a 
recognised overseas reference 
laboratory
• Local laboratory presumptive 
identification of Salmonella 
typhi or paratyphi on faecal 
and/or blood culture or 
culture of another sterile site 
(e.g. urine), with or without 
clinical history compatible 
with enteric fever
OR
• A returning traveller giving 
a clinical history compatible 
with enteric fever and docu-
mentation of a positive blood/
faecal culture (or positive 
PCR for S. typhi / S. paratyphi 
on blood) and/or treatment 
for enteric fever overseas
• A person with a clinical history 
compatible with enteric fever 
and where the clinician sus-
pects typhoid or paratyphoid as 
the most likely diagnosis
OR
• A person with clinical history 
of fever and malaise and/or 
gastrointestinal symptoms with 
an epidemiological link to a 
source of enteric fever e.g. if 
they have ‘Warn and inform’ 
information
OR
• A returning traveller reporting 
a diagnosis abroad with 
positive serological testing or 
Salmonella PCR from faeces but 
no documented evidence of a 
positive blood or faecal culture 
positive
Table 1. 
PHE classification of Enteric fever cases
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organisation (WHO) is blood culture, although this may be culture of bone mar-
row, stool or urine depending on the time in the course of infection at which the 
sample was taken [4, 7, 15]. Even blood culture has been found to be an imperfect 
gold standard, hence there is an advocacy in some quarters for the use of a com-
posite reference standard (CRS) to improve estimation of diagnostic accuracy [19]. 
The CRS involves combination of several diagnostic tests to increase the sensitivity 
rather than relying on individual tests. However, at present there is no consensus 
as to which tests should be included in the CRS [19]. This may be the future gold 
standard but further research is needed.
In low- and middle-income countries where the disease is endemic, access 
to contemporary diagnostic tests may be a challenge and a lot of patient in these 
countries pay out of pocket for health service delivery which they may not be able 
to afford. Hence, there is a case for empirical treatment based on clinical symp-
toms. However, this should be seen as a last resort and priority should be given to 
improving access to a simple, effective rapid diagnostic test (RDT) which is both 
reliable and valid. At present, although there are RDTs available commercially in 
endemic areas such as Typhidot, TUBEX and Test-it, their diagnostic accuracy is 
uncertain [20].
A lot of laboratories in low resource settings are still very much dependent on 
the Widal test. The Widal test is a serologic agglutination test developed by F Widal 
in 1896 [21]. The test is based on the presence of antibodies against the flagellar 
H and somatic O antigens of Salmonella typhi. Over the years, it has become a lot 
more controversial and largely abandoned in developed countries [21]. The main 
limitations with the test include a high cross- reactivity with other infectious agents 
(like nontyphoidal salmonella, plasmodium and tuberculosis), past enteric fever 
and BCG vaccination history. Other limitations include poor performance technique 
and result interpretation. Therefore, its use should be restricted to situations where 
there is no other supportive confirmatory test [21].
There are lots of other tests in development which hold promise for the future 
of enteric fever diagnosis. The antibody-in lymphocyte-supernatant (ALS) test has 
demonstrated good sensitivity and specificity in endemic settings [7, 22]. Others 
include PCR-based assays and high through-put technologies on clinical specimens 
using mass spectrometry [23].
6. Clinical management
In primary care, a thorough history and clinical examination could be sugges-
tive. Unstable patients or those at high risk of deterioration should be referred to 
secondary care for same day hospital assessment and treatment. The mainstay of 
enteric fever treatment is antibiotics. The route of administration is often oral and 
parenteral in primary and secondary care respectively. There are several options of 
antibiotics and first line choice is usually determined by national and local guide-
lines according to sensitivities and antibiotics resistance pattern. In most places, 
fluoroquinolones such as ciprofloxacin and ofloxacin are first line. Second line 
antibiotics include third generation cephalosporins such as ceftriaxone, ampicillin, 
co-amoxiclav and trimethoprim-sulphamethoxazole [7]. Over the years, several 
options of antibiotics have been preferred but have changed based on resistance 
patterns. Decades ago, top on the list of antibiotics were chloramphenicol, ampicil-
lin and co-trimoxazole [7]. The resistance to these traditional antibiotics resulted in 
multidrug resistance (MDR) typically conferred via IncHI1 plasmids, harbouring 
resistance genes such as catA, sul1, sul2, dfrA, blaTEM-1, strA, strB, tetA, tetB, tetC, 
and tetD on composite transposons [7]. MDR strains were responsible for several 
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outbreaks of enteric fever in the 1980/1990s and led to the widespread use of fluo-
roquinolones as first-line therapy [7, 24]. In the event of MDR and fluoroquinolone 
resistance, third generation cephalosporins provided respite and an effective alter-
native. Unfortunately, there are now emerging resistant strains to fluroquinolone 
and cephalosporin especially in Africa, south-east Asia and the Indian subcontinent 
resulting in extreme drug-resistance [7]. Fluoroquinolone resistance occurs mainly 
via chromosomal mutations in the gyrA, gyrB, parC, and parE genes. The local 
pharmacologist or microbiologist should be involved in discussion of the treatment 
of such cases where recommendations can be made for the use of other options. 
Such options would likely include Azithromycin, tigecycline or the monobactam, 
Aztreonam. On a positive note, re-emerging sensitivity to the traditional antibiotics 
of chloramphenicol, ampicillin and co-trimoxazole is being reported after the pro-
longed decline in their use [25]. This makes a case for strict adherence to antibiotics 
stewardship and similar trend may be the case for lot of other infectious diseases 
which is worth exploring. It is inevitable that various forms of MDR may emerge in 
future and antibiotic guidelines have to evolve to reflect the trend.
Also, chronic carriers may be treated with a combination of medical and surgical 
interventions. About 80% clearance rate can be achieved with a 28- day course of 
ciprofloxacin 750 mg twice daily or norfloxacin 400 mg twice daily. Azithromycin 
may be beneficial in those with floroquinolone resistance. In chronic carriers with 
cholethiasis, cholecystectomy under antibiotic cover is indicated and those with 
schistosomal infection should be covered with praziquantel [7, 24].
7. Prevention
As earlier discussed, central to the transmission and pathogenesis of enteric 
fever is poor sanitation and hygiene standards and lack of access to safe drinking 
water. Therefore, public health interventions targeted at addressing these will go a 
long way in reducing the global burden of the disease.
Another factor responsible for high global burden is the emergence of antimi-
crobial resistance strains which result in treatment failure and increased carriage 
rate [7, 14, 16]. In light of this, it is totally rational that the development of a highly 
efficacious vaccine will significantly reduce global burden. This is highly important 
especially for endemic areas with high disease burden and those at high risk of 
complications especially young children. A number of typhoid vaccines have been 
developed over the years and others are still in various stages of development with 
varying degrees of efficacy. Examples include Ty21a and Vi-polysaccharide vaccines 
which have shown efficacy at 2 years of 58% (95% CI 40–71%) and 59% (95% CI 
45–69%), respectively [7]. Typhoid conjugate vaccines (TCVs) have been devel-
oped using the Vi-polysaccharide vaccine covalently linked to a protein to enhance 
immunogenicity, antibody quality, magnitude and duration [7]. Recent studies 
have shown better and long-lasting immunogenicity from TCV than Vi alone. For 
instance a prototype Vi-rEPA vaccine made up of Vi covalently linked to rEPA, a 
recombinant exoprotein A from Pseudomonas aeruginosa demonstrated efficacy 
of up to 91% (95% CI 77–97%) at 2 years, when given as a two dose schedule in 
2–5 year-old children and protection lasted at least 4 years [7, 26, 27].
In England, the two main vaccines available are the Vi vaccine given as a single 
injection and the Ty21a vaccine available in the form of three capsules to be taken 
on alternate days. It is also available in combination with hepatitis A vaccine with 
protection lasting 1 year and 3 years for hepatitis A and Typhoid respectively [28]. 
Vaccination is highly recommended for people who are travelling to high risk areas 
including the Indian subcontinent, Africa, South America, South and South-east 
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Asia [28]. The Ty21a being live-attenuated, should not be given to immunocompro-
mised patients or children below six years of age. However, the Vi vaccine can be 
given from the age of 2 years [28].
The World Health Organisation (WHO) strategic Group of Experts on immuni-
sation, in October, 2017, recommended the inclusion of TCVs in vaccination 
programme schedules in endemic countries from 6 month of age and catch-up 
vaccinations in children and adolescents up to 15 years old where it is feasible and 
appropriate [7, 29]. However, this is yet to be implemented in most of these coun-
tries due to several factors including lack of political will, poor funding and in some 
cases poor uptake due to local cultural beliefs.
In 2008, the Vaccine Alliance (Gavi) made TCVs a priority as part of the typhoid 
investment initiative but did not make any financial commitments due to unavail-
ability of a suitable vaccine [29], however, with the development of promising 
vaccine candidates with clinically appreciable efficacy albeit in the short- to- 
medium term, in November 2017, Gavi committed an $85 million funding window 
to support the roll out of these vaccines in eligible countries between 2019 and 2020 
[7, 29] and in In January 2018, the WHO prequalified the TYPBAR-TCV. Since then, 
three countries have applied for support from Gavi, which includes a request for 
TCV use in response to an outbreak. The first Gavi-supported introduction of the 
TCV began in 2019 with Pakistan being the first country to request the vaccine in 
response to widespread transmission of an of extreme drug resistant strain (XDR) 
of Salmonella typhi. Following on this in the same year, Zimbabwe also applied for 
the TCV to combat an outbreak of drug resistant strains in Harare and was the first 
non-research use of the TCV in sub-Saharan Africa [29]. It is hoped that many more 
countries will apply for vaccine support and increase coverage to enhance reduction 
in global disease burden.
Another important factor driving an increase in disease burden is antibiot-
ics resistance. This is mainly in endemic countries where the implementation of 
antibiotic stewardship is still a huge challenge. In these areas, a lot of antibiotics 
can be bought over-the-counter and patients often get them from the local chemist 
or patent medicine store without having to see a clinician. This has fostered the 
propagation of drug resistant strains of Salmonella typhi and paratyphi resulting in 
treatment failure, increased morbidity and mortality and increased tendency for 
chronic carriage. To mitigate this, there has to be a deliberate policy in these coun-
tries to better control access to antimicrobials, improved access to rapid diagnostic 
tests and public sanitation measures like clean, safe water, running pipe-borne 
water, clean toilet and waste disposal facilities.
8. Conclusion and recommendation
In conclusion, enteric fever caused by Salmonella typhi and paratyphi is still a 
huge global challenge and remains of major public health concern especially in low 
resource settings. The fundamental reasons for this unrelenting disease burden are 
multifactorial. Major factors include poor hygiene and sanitation measures, lack of 
access to portable drinking water, antibiotics resistance and poor access to vaccines. 
There has to be a strong political will for disease surveillance and primary care 
interventions such as ensuring the typhoid vaccines are included in routine immun-
isation schedules in endemic countries especially for children. The traditional 
typhoid vaccines held some challenges including convenience of administration and 
poor immunogenicity. However, the TCVs with better administration convenience 
especially in children as young as six months and longer-term protection, hold huge 
promise for the future of typhoid vaccine prophylaxis. Also, more countries need 
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to seize the opportunity for vaccine support provided by Gavi to improve vaccine 
uptake. There also has to be increased investment in research and development 
into novel vaccines and diagnostic tools which are accessible, available, reliable and 
affordable. With the aforementioned and improved commitment to environmental, 
food and hygiene status, we will hopefully combat this scourge and forge a better, 
healthier future with enteric fever disease burden reduced to the barest minimum.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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